Tabuk Makes MENA Deal For Prestige’s Trastuzumab
Pair Strike Agreement On Rights To Tuznue Biosimilar To Herceptin
Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.
You may also be interested in...
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.
Prestige BioPharma has struck a deal with Pharmapark to market Prestige’s trastuzumab biosimilar in the Russian Federation.